Pharmacotherapies for Retinal Detachment.

Thomas J Wubben, Cagri G Besirli, David N Zacks

Journal: Ophthalmology 2017;123(7):1553-62

PMID: 27040150

Full Text on Elsevier Science View on PubMed

Abstract

Retinal detachment is an important cause of visual loss. Currently, surgical techniques, including vitrectomy, scleral buckle, and pneumatic retinopexy, are the only means to repair retinal detachment and restore vision. However, surgical failure rates may be as high as 20%, and visual outcomes continue to vary secondary to multiple processes, including postoperative cystoid macular edema, epiretinal membrane formation, macular folds, and, ultimately, photoreceptor death. Therefore, pharmacotherapies are being sought to aid the success rates of modern surgical techniques and reduce or slow the degeneration of photoreceptors during retinal detachment. This review discusses potential therapeutic avenues that aid in retinal reattachment, reduce the rate of retinal redetachment by limiting proliferative vitreoretinopathy, and protect against photoreceptor cell death.

Address: Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan. Electronic address: [email protected].

DOI: 10.1016/j.ophtha.2016.02.040

Link outs

Free resources

Medical:

https://medlineplus.gov/retinaldetachment.html

Other Literature Sources:

Subscription / membership required

Full Text Sources:

MeSH Terms: Angiogenesis Inhibitors, Anti-Inflammatory Agents, Enzyme Inhibitors, Humans, Integrin alpha5beta1, Neuroprotective Agents, Oxygen Inhalation Therapy, Retinal Detachment